July 13, 2011

Product recalls over the past two years have eroded consumer trust in over-the-counter drugs; however, those same recalls represent opportunity for smaller market players to gain exposure and build brand awareness, wrote Laura Mahecha, industry manager for health care at research firm Kline, in an online report issued Wednesday.

July 5, 2011

The Food and Drug Administration has approved a drug made by Novartis for treating chronic obstructive pulmonary disease, the FDA said Friday.

June 20, 2011


Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.


June 8, 2011

The Food and Drug Administration has approved a generic oral contraceptive made by Sandoz, the company said Wednesday.

June 6, 2011

The Food and Drug Administration has approved a dozen new generic versions of a drug used to treat breast cancer, the agency said Monday.

June 2, 2011

A class of drugs commonly used to control blood pressure does not increase patients’ risk of developing cancer, according to the Food and Drug Administration.

June 1, 2011

Sandoz has launched generic versions of treatments for Alzheimer’s disease, the generic pharmaceuticals division of Swiss drug maker Novartis said Wednesday.

May 23, 2011

The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


May 23, 2011

The Food and Drug Administration has approved a Pfizer drug for treating pancreatic tumors.

May 20, 2011

Sandoz is looking to market a generic version of a Shire drug for treating attention deficit hyperactivity disorder.

May 12, 2011

A blood pressure drug made by Swiss drug maker Novartis has won an award from the Healthcare Compliance Packaging Council.

May 6, 2011

The Food and Drug Administration has approved a drug made by Novartis as the first treatment for advanced pancreatic neuroendocrine tumors, Novartis said Thursday.

May 4, 2011

Novartis is making big investments in biosimilars, CEO Joe Jimenez said in an interview with Fortune magazine.

May 4, 2011

The Food and Drug Administration has approved a generic oral contraceptive made by Sandoz, the generics arm of Swiss drug maker Novartis said Wednesday.

April 27, 2011

OTC Perspectives magazine on Tuesday named its third annual list of "Top OTC/HBA Marketers of the Year."

April 25, 2011

Mylan has launched a generic treatment for breast cancer, the drug maker said Monday.

April 11, 2011

The Food and Drug Administration has approved an oral contraceptive made by Sandoz, the company said Friday.

April 5, 2011

Mylan subsidiary Bioniche Pharma has launched an injectable treatment for a rare metabolic disorder, Mylan said Tuesday.

March 24, 2011

The Food and Drug Administration has extended its regulatory review period for Novartis' new drug application for its once-daily, long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, as well as chronic bronchitis and/or emphysema, the drug maker said.

March 24, 2011

Sandoz has introduced an authorized generic version of a herpes treatment made by parent company Novartis, the company said Thursday.

March 22, 2011

A subsidiary of Watson Pharmaceuticals has launched a treatment for herpes infections, the company said Monday.

March 7, 2011

The OTC Pain Relief Ingredient Guide breaks down the indication, active ingredients, purpose and dosage of OTC internal and external analgesics.

March 2, 2011

A group of drug makers have sued Mylan over its attempt to gain Food and Drug Administration approval for a generic menopause drug, Mylan said Tuesday.

February 18, 2011

Though efforts to repeal the Patient Protection and Affordable Care Act via the court system remain under way — with recent victories for opponents in Virginia and Florida — the attempt to repeal the healthcare-reform bill in Congress failed, thus leaving the bill and, most importantly, the regulatory approval pathway for follow-on biologics intact.